Although much remains unknown about many mutations and test results rarely clarify the need for any particular response, panel testing has already demonstrated its cost value, which continues to increase every day.
Original Article: Scarcity of Actionable Oncogenes Should Not Preclude Testing
NEXT ARTICLE